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Introduction {#s01}
============

This short commentary will attempt to provide an up-to-date overview of the contribution of various immune cell types to the defense against HCMV, a very common human DNA virus, which has probably co-evolved with its host since the very beginning of human life \[[@bib-001]\]. However, although HCMV is almost a "part" of humankind, not everybody is infected. On a global scale, HCMV\'s most damaging impact is related to birth defects, including gross abnormalities but also sensorineural hearing loss leading to a learning disability that is sometimes discovered quite late \[[@bib-002]-[@bib-004]\]. In addition, HCMV infection is dangerous if immunity is compromised (for example, in the post-transplant setting or HIV infection, situations in which it may cause severe end-organ disease) \[[@bib-005],[@bib-006]\].

Over the last decade or so, HCMV has been linked to premature aging of the immune system ("immunosenescence") as well as premature clinical manifestations of vascular pathology, particularly in the context of HIV infection \[[@bib-007]-[@bib-011]\]. HCMV is noted for sometimes inducing very large T cell responses but at the same time for possessing multiple immune evasion mechanisms \[[@bib-012]\]. The best known of these is probably latency, a "sleep-like" state with limited protein expression \[[@bib-013]\].

For a long time, "classic" cytotoxic alpha/beta (α/β) CD8 T cells, recognizing lytic-phase HCMV antigens, were thought to be the mainstay of cellular anti-HCMV immunity \[[@bib-014],[@bib-015]\]; however, over the last decade or so, HCMV-specific CD4 T cells have been given increasing attention as they not only contribute cytotoxic activity in addition to "classic" helper function but also are a lot more numerous than previously thought. Of note, CD4 T cells recognizing HCMV proteins expressed during latency were very recently described. A subpopulation of these are thought to help HCMV remain sheltered from the immune response \[[@bib-016]\].

A more recent discovery is a subset of HCMV-induced regulatory T (iTreg) cells that probably develop from conventional antigen-activated CD4 T cells \[[@bib-017],[@bib-018]\]. However, this area is controversial as no widely accepted general definition of inducible iTregs exists in the literature, especially not in humans. Among T cells, γ/δ T cells have been characterized that initially appeared to be specific for HCMV but now are understood to recognize stress antigens expressed (for example, by HCMV-infected cells) \[[@bib-019],[@bib-020]\]. While natural killer (NK) cells are widely recognized as a first-line innate defense against HCMV, recent reports provide scope, at least in theory, for an HCMV-specific major histocompatibility complex/killer cell immunoglobulin-like receptor (MHC/KIR)-mediated interaction contributing to silencing this response \[[@bib-021]\].

To briefly mention technology, much of the work done in this area over the last 20 years or so has hugely benefitted from the advancements in antigen-specific immunology made in the 1990s. The approaches that have made most of the difference exploring T cell responses in the HCMV T cell field were MHC multimer-based approaches \[[@bib-022]\] and functional approaches like intracellular cytokine staining following *in vitro* stimulation with HCMV antigens (in particular, protein-spanning peptide pools) or infected cells \[[@bib-023]-[@bib-027]\]. The MASIR (measuring antigen-specific immune responses) series of five conferences between 2005 and 2013 was focused on the measurement of antigen-specific immune responses and produced a number of reviews providing a good overview of current technology in this field \[[@bib-028]-[@bib-030]\].

Classic effector and helper T cell responses to human cytomegalovirus infection {#s02}
===============================================================================

Throughout the 1990s, research exploring human HCMV T cell target antigens focused essentially on two major protein targets: the pp65 lower matrix phosphoprotein (UL83, referred to as "pp65" in this review) and the 72 kDa immediate early protein, IE-1 (UL123, referred to as "IE-1" in this review) \[[@bib-031]-[@bib-034]\]. The focus of research during this period was clearly on the "cytotoxic" CD8 T cell response. It is now clear that a broader range of antigens and cellular functions has to be taken into account. In the past, responses to epitopes presented by HLA-alleles common in Western Europe and parts of the United States (e.g. HLA-A\*0201) were prioritized in research because they are easy to study.

CD4 T cells have not usually been implicated in HCMV-specific cytotoxicity to the same extent as CD8 T cells, despite the fact that lysis of HCMV-infected cells by CD4 T cells was described as early as 1986 \[[@bib-035]\]. CD4 T cell cytotoxicity was discovered even earlier \[[@bib-036]\]. Using modern technology, Appay *et al.* confirmed in 2002 that CD28^−^ CD4 T cells (a hallmark of HCMV infection) had the ability to lyse target cells \[[@bib-037]\], and in the last 10 years or so, more and more researchers "rediscovered" CD4 T cell responses to HCMV. Experimental adoptive T cell transfer in bone marrow transplant patients in the early 1990s had already suggested that CD4 T cells are very important but their main task was believed to be the upkeep of CD8 T cell immunity \[[@bib-038]\]. In 1996, it was shown that stimulation of peripheral blood mononuclear cells with HCMV viral lysate was able to activate very large numbers of CD4 T cells based on intracellular cytokine staining (ICS); however, the full extent of CD4 T cell involvement in the immune response to HCMV was not clear until a landmark publication in 2005 \[[@bib-027]\] changed our perspective entirely, in regard to both CD4 and CD8 T cells. By screening the HCMV proteome using 213 protein-spanning peptide pools \[[@bib-026]\], it was revealed that human T cells recognized at least 151 proteins in a donor population of 33 individuals of mixed MHC backgrounds. CD4 T cells recognized 125 proteins, CD8 T cells recognized 107 proteins, and 81 proteins were recognized by both. Of note, until recently, the size of the HCMV proteome was somewhat underestimated. A recent publication estimated that the HCMV genome provides more than 700 protein open reading frames, potentially coding for many previously untested proteins as well as smaller proteins overlapping with previously known ones \[[@bib-039]\]. Being a very large DNA virus, HCMV adapts to the host through immune evasion rather than rapid mutation of target proteins \[[@bib-040]\]. Nevertheless, the HCMV-specific T cell response targets mostly proteins that are highly conserved between different HCMV strains \[[@bib-027]\]. There is a tendency for CD4 T cells to predominantly recognize structural (virion) proteins and for CD8 T cells to predominantly recognize non-structural proteins; however, there is huge overlap between the compartments. In addition to dendritic cell cross-presentation, there are ways in which a HCMV antigen is "packaged" to overcome the divide of exogenous and endogenous antigen-presenting pathways. For example, dense bodies are particles full of HCMV proteins that are secreted by infected cells. They are internalized by antigen-presenting cells \[[@bib-041],[@bib-042]\] essentially moving endogenous antigens into the exogenous pathway. Non-infectious enveloped particles secreted by infected endothelial cells appear to have a similar function \[[@bib-043]\].

Preferences for proteins of certain kinetic classes to some extent relate back to their structural and non-structural nature (for example, a preference for \[non-structural\] immediate early proteins to be recognized by CD8 T cells); however, CD4 T cells can also recognize these and no strict divide seems to exist \[[@bib-027]\].

T cell responses to HCMV latency-associated proteins were somewhat "neglected" in the past, mostly because the identification of latency antigens was delayed compared with lytic-phase antigens \[[@bib-044]\]. Not many latency-associated antigens are known to date, but Mason *et al.* recently reported that some of these are recognized by CD4 T cells \[[@bib-016]\]. Their work focused on two proteins in particular---UL138 and LUNA (latency-associated unidentified nuclear antigen)---both of which are expressed during lytic infection and latency. CD4 T cells recognizing UL138 and LUNA were detected in the first instance by interferon-gamma (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assays. In lieu of using complete proteins, the authors used protein-spanning overlapping peptide pools for stimulation \[[@bib-026]\]. More detailed analysis, however, revealed that, unlike CD4 T cells specific to a lytic-phase antigen like glycoprotein B, *ex-vivo* expanded CD4 T cells specific for LUNA or UL138 also produced IFN-γ when stimulated by latently infected autologous monocytes. Interestingly, some of these cells also produced cellular IL-10 (cIL-10) and transforming growth factor-beta (TGF-β), suggesting that they would subdue T cell responses rather than accelerate them. These findings were confirmed for two additional latency-associated proteins, US28 and vIL-10, which in summary suggests that latency-associated antigens prime subpopulations of CD4 T cells with a functional pattern "protective" of HCMV.

Despite huge efforts, the overall workings of the T cell response to HCMV are still understood poorly at best. If there is anything, such as a "formula", that will allow us to recognize whether the HCMV-specific T cell response in a given individual is in control of HCMV or not, it certainly has not been discovered yet. In humans, one usually has to work with phenomenological/correlative results. If such results are good enough to develop reliable clinical diagnostic tools, they are indeed very useful. This should, however, not be confused with an understanding of basic underlying mechanisms. For example, the monitoring of HCMV-specific CD8 T cells after bone marrow transplantation with a set of class-I MHC multimers provided a reasonable surrogate for "protective" immunity; however, it did not demonstrate that the T cells being monitored actually had any effect \[[@bib-045]\]. In a different study, the adoptive transfer of MHC-multimer-selected pp65-specific T cells after bone marrow transplantation provided protection from HCMV disease, suggesting that pp65-specific T cells can control HCMV infection \[[@bib-046]\]. Conversely, however, patients may develop overt HCMV disease in the face of even large pp65-specific T cell responses, suggesting that these cells do not necessarily always control infection \[[@bib-047]\].

Immune evasion mechanisms versus success of the cellular immune response to human cytomegalovirus {#s03}
=================================================================================================

CMV disposes of a large array of strategies to avoid an efficient immune response and these are thought to be the reason for its successful survival in both human and animal populations. Latency appears to be a particularly important part of the ability of HCMV to hide from the immune system; however, the number of evasion mechanisms is such that this fascinating topic has warranted more reviews than can possibly be referenced here \[[@bib-012],[@bib-048]-[@bib-054]\]. The fact that HCMV-infected people usually do not have HCMV-related health problems seems to confirm that the immune response generally keeps the upper hand, while the success of adoptive T cell transfer therapy in preventing acute HCMV-related complications after bone marrow transplantation underscores the efficiency of T cells in controlling CMV \[[@bib-055]-[@bib-057]\]. However, large investigations into different populations of older people have shown that being HCMV-positive at an older age may be a considerable disadvantage \[[@bib-007],[@bib-058]-[@bib-061]\]. At this time, though, it is unclear to what extent this is related to the virus itself or to HCMV-specific immunity. It may be that very large HCMV-specific T cell responses, which are found in many (particularly older) individuals, are neither required nor beneficial but actually cause damage \[[@bib-062]-[@bib-064]\]. Some researchers believe that excessive T cell responses may be the cause of HCMV-associated premature immune senescence \[[@bib-011]\], and there is some evidence to suggest that how the immune system responds to HCMV determines the degree of such immune senescence rather than infection per se \[[@bib-065]\]. Large T cell expansions are often oligoclonal \[[@bib-066],[@bib-067]\] and their phenotype is CD57^+^ (a marker associated with HCMV carrier status) \[[@bib-068]\] and CD28- \[[@bib-069]\]. The presence of a terminally differentiated CD4^+^CD28- ("CD28 null") subpopulation is actually a hallmark of HCMV infection \[[@bib-070]\], and as a result, the appearance of such cells in vascular autoimmune disease (for example, Wegener\'s granulomatosis) has drawn attention to a possible role of HCMV in these situations \[[@bib-071],[@bib-072]\].

Very large expansions of HCMV-specific T cells are sometimes referred to as "memory inflation", a concept originally derived from inbred mouse models. Many authors have indeed used inbred mice infected with murine CMV (MCMV) to model the situation that occurs in HCMV-infected humans. "Memory inflation" thus describes the increase of T cell responses to certain epitopes over time and their long-term maintenance at high frequencies \[[@bib-073]-[@bib-075]\]. In mice, unlike in humans (where the time of infection is usually not known), this phenomenon can be studied longitudinally. There are a number of obvious differences between inbred mice and humans as there are between MCMV and HCMV, but essential response mechanisms are still thought to be very similar. Compared with human models, inbred mouse models have the advantage that they produce predictable T cell response patterns that are useful for studying T cell immunity, albeit in a reductionist way \[[@bib-073],[@bib-076]\]. Other animal models are also being used to study T cell immunity after CMV infection, including rats \[[@bib-077],[@bib-078]\] and non-human primates \[[@bib-079]\]. Using rhesus CMV (RhCMV) as a vector in a novel and highly effective simian immunodeficiency virus (SIV) vaccine has exploited the fact that CMVs attract large and persistent T cell responses \[[@bib-080],[@bib-081]\].

Cytomegalovirus-induced regulatory T cells {#s04}
==========================================

Recent years have seen an explosion of information on the critical role of regulatory T cells (Tregs) in the control of T cell effector responses, peripheral tolerance, and immune homeostasis. Tregs can develop in the thymus (natural Tregs, or nTregs) or can be induced in the periphery by the antigen activation of naïve T cells (inducible Tregs, or iTregs) in response to a variety of conditions, as recently reviewed by Bilate *et al.* \[[@bib-082]\]. In particular, iTregs can be generated in response to sub-immunogenic doses of antigen \[[@bib-083]\] and chronic inflammation, as has been observed in several infections \[[@bib-084]-[@bib-086]\]. It is believed that the expansion of iTregs in infection has the beneficial role to limit the magnitude and duration of inflammatory responses and consequential tissue damage and at the same time drive the establishment of chronic infection. Tregs appear to control the activation of effector T cell responses by competition for growth factors, secretion of soluble factors, and cell-cell interaction. The expression of the high-affinity IL-2 receptor CD25 allows Tregs to decrease the local concentration of IL-2, an essential growth factor for effector cells. Among other mechanisms, Tregs also express relatively high levels of cytotoxic T-lymphocyte antigen 4 (CTLA-4), an extrinsic regulator of T cell responses \[[@bib-087],[@bib-088]\], and through CTLA-4 stimulate dendritic cells (DCs) to produce the enzyme indoleamine 2,3-dioxygenase, which degrades the essential amino acid tryptophan into pro-apoptotic kynurenine \[[@bib-089]\]. The ectonucleotidase, CD39, equally expressed on Tregs, catabolises inflammatory ATP to anti-inflammatory adenosine \[[@bib-090],[@bib-091]\].

We currently lack reliable phenotypic markers for the discrimination of iTregs and nTregs. Moreover, the identification of iTregs is complicated by the existence of alternative subpopulations that include but are not limited to IL-10-producing Tr1 and TGF-β-producing Th3 cells \[[@bib-092],[@bib-093]\]. Among the expression markers associated with Tregs, the forkhead transcription factor FoxP3 (forkhead box P3) was once considered a "benchmark" identifier as it was believed to be essential for Treg development \[[@bib-094]\]. However, FoxP3 is also (transiently) upregulated on activated CD4 T cells and not necessarily stably expressed in populations of suppressive iTregs \[[@bib-095]-[@bib-097]\]. Alternative markers, such as the transcription factor Helios (Izf2) \[[@bib-098]\] and the surface protein neuropilin-1 \[[@bib-099]-[@bib-101]\], have, likewise, remained unsatisfactory for the discrimination of nTregs and iTregs.

We have recently identified a population of antigen-activated iTreg cells by combining canonical Treg markers, CD25 and CD39, with the activation marker CD134 (OX40) \[[@bib-017],[@bib-102]\]. Interestingly, iTregs defined this way were increased in HCMV-infected older people and associated with increased resting blood pressure, suggesting a role of HCMV in driving vascular changes in older life. These findings add to a number of published articles associating HCMV infection with vascular complications \[[@bib-009],[@bib-010]\]; however, no direct link between the T cell response to HCMV and blood pressure had previously been made.

Other cellular responses to human cytomegalovirus infection: γ/δ T cells and natural killer cells {#s05}
=================================================================================================

γ/δ T cells are not normally frequent in peripheral blood but are very frequent in gut epithelium \[[@bib-103]\]. Among γ/δ T cells, the Vδ2^-^ population is of particular interest in HCMV infection because its long-term expansion is almost like a signature of HCMV infection \[[@bib-020]\]. Recently, major inroads into the cognate ligands of this population in the context of HCMV infection were made \[[@bib-019]\]. While these cells are not strictly speaking HCMV-specific, they can effectively lyse HCMV-infected fibroblasts and endothelial cells as a result of a cellular stress response that leads to the upregulation of endothelial protein C receptor (EPCR) plus co-stimulatory molecules like CD54 (ICAM-1). Earlier reports suggested that a Vγ9^-^ γ/δ T cell population including Vγ8 Vδ1 cells with a "public" Vδ1 complementarity determining region 3 T cell receptor (TCR) sequence plays a role *in utero* in congenital HCMV infection; however, the antigen recognized by these cells has not been identified yet \[[@bib-104]\].

NK cells belong to the innate immune response and are equipped with receptors exhibiting much less polymorphism than the TCR. They express a range of inhibitory and activating surface receptors, including lectin-like receptors and Ig-like receptors (KIRs). The inhibitory lectin-like receptor CD94/NKG2A/B interacts with the (non-classic) class Ib MHC molecule HLA-E, stable expression of which depends on the presentation of (classic) class Ia MHC molecule leader sequences. However, HLA-E can also be upregulated/stabilized by an HCMV-encoded peptide that is part of the glycoprotein UL40 sequence, a protein involved in immune evasion \[[@bib-105],[@bib-106]\]. It is interesting that HCMV infection leaves a stable imprint on the KIR repertoire in infected individuals involving the activating KIRs, KIR2DS4, KIR2DS2, and KIR2DS1. This suggests that certain NK cells are indeed selected by HCMV infection \[[@bib-107]\]. These mechanisms are nowhere nearly as specific as TCR/MHC/peptide interactions; however, there is clearly an element of specificity and "memory" usually not associated with innate immunity. NK cell memory is a fairly recent discovery in a rapidly evolving field \[[@bib-108]\]. Recently, NK cell specificity was reported from the HIV field as it was shown that an HIV-1 p24-derived epitope can be presented by HLA-Cw\*0102 and modulate the NK cell response via the ligand KIR2DL2 \[[@bib-021]\]. Similar mechanisms may be active in HCMV infection, but this field is only beginning to be explored.

Conclusions and outlook {#s06}
=======================

In summary, we still lack a real understanding of how the cellular immune response to CMV is actually organized and functions as a whole to provide protection. Many inroads have been made into understanding individual immune response elements (commonly studied aspects involving target specificity, response size, avidity, functionality, phenotype, and clonality); however, the next step needs to be the integration of these elements into a bigger picture. In order to make a real difference, we need to understand the correlates of protection. This would critically improve the management of patients and assist an effective CMV vaccine design.
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